Navigation Links
S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
Date:12/2/2009

of pharmacodynamic (PD) biomarker assays for SB1518 will be presented in a poster, demonstrating PD target efficacy of SB1518 in animal tumor models, as well as, in patients in ongoing Phase 1 clinical studies for advanced leukemias, myeloproliferative diseases and lymphoma. The fourth poster will highlight the effects of SB1518 on ex vivo expanded polycythemia vera (PV) erythroid progenitors which correlate with clinical observations.

Poster No.: 3905, Time: 6-8 p.m. CST, Monday, Dec. 7, 2009, Location: Hall E (Ernest N. Morial Convention Center)

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis

SB1518, which is a potent ATP-competitive inhibitor of JAK2 (IC50=22nM), JAK2V617F mutant (IC50=19nM), FLT3 (IC50=22nM) and its mutant D835Y (IC50=6nM), is being tested to determine its safety, tolerability and PK/PD profile when administered orally once daily continuously in 28-day cycles. SB1518 was well tolerated at doses up to 500 mg daily in patients with advanced myelofibrosis (MF) and acute myelogenous leukemias (AML), and shows clinical activity in MF patients with splenomegaly.

Oral Presentation Abstract No.: 588, Time: 4 p.m. CST, Monday, Dec. 7, 2009, Location: Room R02-R05

Phase 1 Study of the Novel Oral JAK2 Inhibitor SB1518 in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity

A Phase 1 dose escalating study of the novel JAK2 small molecule inhibitor SB1518 is being conducted in patients with relapsed Hodgkin (HL) and non-Hodgkin lymphomas (NHL). The primary objectives are to examine the safety and efficacy of SB1518 in this patient population. Patients are treated at four dose levels (100 mg, 200 mg, 300 mg, and 400 mg) orally daily without interruption.
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
2. S*BIO Completes US$26 Million Equity Financing
3. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
4. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
5. Novel Technology Breaks Through Cancer Pain
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
9. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
10. NIST team develops novel method for nanostructured polymer thin films
11. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... California (PRWEB) July 31, 2014 CollabRx, ... that inform therapeutic decision-making in oncology, today announced that ... 14, 2014 to discuss the Company's financial results for ... an update about the business in the current fiscal ... call beginning on Thursday, August 14, 2014, at 5 ...
(Date:7/31/2014)... , July 31, 2014  Smith & Nephew ... medical technology business, today announced its entry into ... HAT-TRICK™ Lesser Toe Repair System. Comprised of three ... for metatarsophalangeal (MTP) ligament repair and reconstruction, a ... for proximal Inter-phalanges (PIP) fusion, also known as ...
(Date:7/31/2014)... Calif. (PRWEB) July 31, 2014 Held ... diagnosed patients with an overview of the disease and ... of drug side effects, as well as updates on ... grateful to Dr. Sandy Srinivas for organizing this educational ... of kidney cancer. “Sandy and her colleagues have put ...
(Date:7/31/2014)... The global market for molecular diagnostics is ... to a new study by Grand View Research, Inc. ... subsequent introduction of advanced cancer diagnostic technologies are expected ... next six years. Moreover, the growing global base of ... with disease triggering lifestyle habits such as smoking and ...
Breaking Biology Technology:CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5
... ... Walker formed MEDS World, LLC, launching innovative odor elimination, exterior plastic trim and headlight ... over fifty years of management experiences, in a myriad of industries, to introduce these ... http://www.meds-world.com , ...
... Fred Hutchinson Cancer Research Center board of trustees today announced ... retire in June 2010. Hartwell, a recipient of the 2001 ... director of the Hutchinson Center since 1997. , ... director of the Center for 12 years. It,s time for ...
... Ga., June 26 Immucor, Inc., (Nasdaq/NM: BLUD), a global ... industry, announced that yesterday the Food and Drug Administration ("FDA"), ... inspection, issued a notice of intent to revoke the Company,s ... and Anti-E (Monoclonal) Blood Grouping Reagent product. The FDA ...
Cached Biology Technology:MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 2MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 3Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010 2Immucor Responds To FDA Notice 2
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... in German . ... similar to a sponge that soaks up liquids. Hence, ... or greenhouse gases. However, loading of many MOFs is ... (KIT) now report in Nature Communications that ... surface. This can be prevented by water-free synthesis and ...
(Date:7/31/2014)... the photovoltaic effect in 1839, humankind has sought to ... its own purposes. In a new research report published ... FASEB Journal , scientists may have uncovered a ... focusing on a naturally occurring combination of lipids that ... over time and across speciessuggests that this specific natural ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3Free pores for molecule transport 2Scientists shine bright new light on how living things capture energy from the sun 2
... of vitamin C were associated with higher levels of high ... issues or death for heart failure patients, in research presented ... to those with high vitamin C intake from food, heart ... intake were 2.4 times more likely to have higher levels ...
... Clinical benefit from use of a novel histone deacetylase ... days after a patient receives treatment. The drug, entinostat, ... a randomized, placebo-controlled study in metastatic breast cancer ... can be predicted shortly after administration. The findings, ...
... Lysmata amboinensis usually live in monogamous pairs, but ... BioMed Central,s open access journal Frontiers in Zoology ... viciously attack and kill each other until only a single ... hermaphrodites. This means that they start out as males but, ...
Cached Biology News:Low vitamin C levels may raise heart failure patients' risk 2Benefit of novel drug in breast cancer seen in blood within weeks 2Violent passions -- jealous cleaner shrimp murder their rivals 2
... Streptavidin-AP Systems provide rapid, precise localization ... in frozen or paraffin-embedded tissue, cytospins ... also facilitate double or triple labeleing ... simultaneously with primary antibodies of different ...
... Streptavidin-HRP Systems provide rapid, precise localization ... in frozen or paraffin-embedded tissue, cytospins ... also facilitate double or triple labeleing ... simultaneously with primary antibodies of different ...
... be used with all 96-well ... stacking of covered plates ... with automated systems ... are available for use with ...
... Chromatography requirements, IonQuest will provide ... The newly developed conductivity detector has ... ultra-low drift . The use ... creates even higher sensitivities for anions, ...
Biology Products: